Skip to main content
NewslettersWatchlist

Novartis Ag ADR(NVS-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low106.13
Day High106.69
Open:106.61
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

Ex-Chinook team launches Borealis Biosciences with $150-million from Novartis, Versant

Group behind one of biggest Canadian biotech takeovers unveils latest addition to Vancouver’s teeming life sciences sector
Motley Fool
Novartis Ag (NVS) Q3 2024 Earnings Call Transcript
Motley Fool
3 Absurdly Cheap Stocks That Pay High Dividends
Motley Fool
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Newswire.ca
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women
Motley Fool
2 Magnificent Dividend Stocks to Buy and Hold Forever
Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
GlobeNewswire
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
GlobeNewswire
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Newswire.ca
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players
BayStreet.ca
Recent Breakthroughs in Cancer Research Could Impact These Key Companies
Yolowire
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives
Barchart
Chart of the Day: Novartis - Take Another Look
Newswire.ca
Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy
Motley Fool
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
Barchart
As Radiotherapy Redefines Cancer Care, Here's the Stock to Buy Near 52-Week Highs
Investor Brand Network
Annovis Bio (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
GlobeNewswire
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Newswire.ca
Exploring New Frontiers in Food Allergy Treatments: Market Set for $14B Growth
Motley Fool
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
Motley Fool
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
Motley Fool
2 Magnificent Stocks to Buy With $500
Baystreet
Wholesale Trade, Housing Starts Next Week

Profile

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.